Evan G. Dick - Oct 22, 2021 Form 4/A - Amendment Insider Report for Context Therapeutics Inc. (CNTX)

Role
SVP of R&D
Signature
/s/ Alex Levit, Attorney-in-Fact
Stock symbol
CNTX
Transactions as of
Oct 22, 2021
Transactions value $
$0
Form type
4/A - Amendment
Date filed
12/17/2021, 03:12 PM
Date Of Original Report
Oct 22, 2021
Previous filing
Dec 17, 2021
Next filing
Feb 17, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTX Common Stock Conversion of derivative security +26.6K +47.16% 83K Oct 22, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CNTX Series Seed Preferred Stock Conversion of derivative security -26.6K -100% 0 Oct 22, 2021 Common Stock 26.6K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.
F2 Includes 33,397 restricted stock units which fully vest on January 31, 2023.
F3 Fully vested.

Remarks:

The attached amends and restates the Form 4 filed on October 25, 2021 in its entirety